Fig. 6
YM101 treatment inhibited tumor growth in murine tumor models. a Exploring the optimal dosage of YM101 in the EMT-6 model. The growth curves of EMT-6 tumors of mice receiving different dosages of YM101. b The body weight change curves of EMT-6-bearing mice receiving different dosages of YM101. c The tumor images of EMT-6-bearing mice receiving the treatment of YM101 or controls. d The tumor growth curves of EMT-6-bearing mice receiving the treatment of YM101 or controls. e The tumor weights of EMT-6-bearing mice receiving the treatment of YM101 or controls. f The tumor images of CT26-bearing mice receiving the treatment of YM101 or controls. g The tumor growth curves of CT26-bearing mice receiving the treatment of YM101 or controls. h The tumor weights of CT26-bearing mice receiving the treatment of YM101 or controls. i The tumor images of 3LL-bearing mice receiving the treatment of YM101 or controls. j The tumor growth curves of 3LL-bearing mice receiving the treatment of YM101 or controls. k The tumor weights of 3LL-bearing mice receiving the treatment of YM101 or controls. l For the rechallenge assay, YM101-cured or treatment-naïve mice were inoculated with 1 × 106 3LL cells on the day 10 after the final YM101 injection. m The tumor images of the 3LL rechallenge assay. n The tumor growth curves of the 3LL rechallenge assay. o The tumor weights of the 3LL rechallenge assay. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1, CR: complete regression